[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR070479A1 - Derivado heterociclico fusionado y su uso - Google Patents

Derivado heterociclico fusionado y su uso

Info

Publication number
AR070479A1
AR070479A1 ARP090100644A ARP090100644A AR070479A1 AR 070479 A1 AR070479 A1 AR 070479A1 AR P090100644 A ARP090100644 A AR P090100644A AR P090100644 A ARP090100644 A AR P090100644A AR 070479 A1 AR070479 A1 AR 070479A1
Authority
AR
Argentina
Prior art keywords
substituent
optionally
fusioned
heterociclic
derivative
Prior art date
Application number
ARP090100644A
Other languages
English (en)
Inventor
Yuya Oguro
Satoshi Sasaki
Nobuhiro Fujii
Shigeru Kondo
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR070479A1 publication Critical patent/AR070479A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Composicion farmacéutica y uso para el tratamiento del cáncer. Reivindicacion 1: Un compuesto caracterizado por la formula (1) en el cual el anillo A es un anillo de 5 a 7 miembros que tiene sustituyente(s) en forma opcional, donde los sustituyentes están unidos en forma opcional entre sí para formar un anillo; X es O, S o NR1 (R1 es un átomo de hidrogeno o un grupo hidrocarburo que tiene sustituyente(s) en forma opcional); R2 es carbamoilo que tiene sustituyente(s) en forma opcional; y R3 es hidroxi que tiene sustituyente(s) en forma opcional, excepto los siguientes compuestos; de formulas (2) o una de sus sales.
ARP090100644A 2008-02-26 2009-02-25 Derivado heterociclico fusionado y su uso AR070479A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008045134 2008-02-26
JP2008256755 2008-10-01

Publications (1)

Publication Number Publication Date
AR070479A1 true AR070479A1 (es) 2010-04-07

Family

ID=40905094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100644A AR070479A1 (es) 2008-02-26 2009-02-25 Derivado heterociclico fusionado y su uso

Country Status (28)

Country Link
US (2) US8399449B2 (es)
EP (1) EP2247588B1 (es)
JP (2) JP4719317B2 (es)
KR (1) KR101569949B1 (es)
CN (1) CN102015705B (es)
AR (1) AR070479A1 (es)
AU (1) AU2009217982B2 (es)
BR (1) BRPI0908417B1 (es)
CA (1) CA2716773C (es)
CL (1) CL2009000429A1 (es)
CO (1) CO6321277A2 (es)
CR (1) CR11661A (es)
DO (1) DOP2010000260A (es)
EA (1) EA020144B1 (es)
EC (1) ECSP10010496A (es)
ES (1) ES2586252T3 (es)
GE (1) GEP20125664B (es)
HK (1) HK1150274A1 (es)
IL (1) IL207735A (es)
JO (1) JO3259B1 (es)
MA (1) MA32164B1 (es)
MX (1) MX2010009372A (es)
MY (1) MY150379A (es)
NZ (1) NZ587719A (es)
PE (1) PE20091556A1 (es)
TW (1) TWI480282B (es)
WO (1) WO2009107850A2 (es)
ZA (1) ZA201006063B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934309B2 (en) 2014-03-31 2021-03-02 Sumitomo Dainippon Pharma Oncology, Inc. Tricyclic quinone derivative

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399449B2 (en) 2008-02-26 2013-03-19 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
NO2459176T3 (es) 2009-07-31 2018-02-24
US20120277238A1 (en) * 2009-07-31 2012-11-01 Shionogi & Co., Ltd Pharmaceutical composition containing fused hetero-ring derivative
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PE20121326A1 (es) 2009-08-26 2012-10-11 Takeda Pharmaceutical Derivados de anillo heterociclico fusionado y uso del mismo
EP2471791B1 (en) 2009-08-26 2014-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US8614208B2 (en) 2009-08-26 2013-12-24 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011024869A1 (ja) * 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2012154731A1 (en) * 2011-05-08 2012-11-15 Vanderbilt University Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
UY34804A (es) 2012-05-11 2013-12-31 Abbvie Inc Inhibidores del nampt
EP3077544B1 (en) * 2013-12-03 2019-04-24 Celestra Life Science LLC Rationale-based design of a targeted therapy for cancer
CN106104865B (zh) 2014-03-19 2018-12-18 株式会社东芝 电池用电极材料、非水电解质电池及电池包
AU2016275764B8 (en) 2015-06-11 2021-03-04 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
US9962378B2 (en) * 2015-09-17 2018-05-08 Macau University Of Science And Technology ROS1 inhibitor and its use
JP6827429B2 (ja) * 2016-02-01 2021-02-10 武田薬品工業株式会社 共結晶
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP7091201B2 (ja) 2018-09-14 2022-06-27 株式会社東芝 活物質、電極、二次電池、電池パック、及び車両
RU2711968C1 (ru) * 2018-11-22 2020-01-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский национальный исследовательский политехнический университет" Анальгезирующее средство
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
CN115997122A (zh) 2020-06-26 2023-04-21 拉夸里亚创药株式会社 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物
CN113292477B (zh) * 2021-06-01 2023-06-02 四川大学 一种铱催化的碳氢活化反应合成异吲哚-1-酮类化合物的方法
CN113429422B (zh) * 2021-07-26 2022-05-10 中国人民解放军军事科学院军事医学研究院 一种噻吩并喹诺酮类化合物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3012684B2 (ja) 1989-12-08 2000-02-28 大日本製薬株式会社 チエノキノリン誘導体、チエノナフチリジン誘導体およびそれらの塩
WO1993013664A2 (en) 1992-01-11 1993-07-22 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
FR2695126B1 (fr) * 1992-08-27 1994-11-10 Sanofi Elf Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant.
JP3223289B2 (ja) 1992-10-22 2001-10-29 東洋アルミニウム株式会社 肉類調理器具および肉類調理方法
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
JP2006151810A (ja) 2002-12-26 2006-06-15 Daiichi Asubio Pharma Co Ltd ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
JPWO2005035516A1 (ja) 2003-10-10 2006-12-21 小野薬品工業株式会社 新規縮合複素環化合物およびその用途
EP1698335A4 (en) 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
KR20060130781A (ko) 2004-04-08 2006-12-19 토포타겟 에이/에스 다이페닐 인돌-2-온 화합물 및 암 치료에 있어서의 그의용도
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2006279536A1 (en) 2005-08-16 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
AR056560A1 (es) * 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
BRPI0707312B1 (pt) * 2006-01-27 2022-06-07 Shanghai Hengrui Pharmacetical Co., Ltd Inibidores de pirrolo [3,2-c] piridina-4-ona 2-indolinona proteína cinase, seu uso e seu processo de fabricação, intermediário e seus processos de fabricação, composição farmacêutica e seu uso
WO2007120827A2 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
EP2134695A4 (en) * 2007-03-14 2011-05-25 Exelixis Inc HEMGE OF THE HEDGEHOG SIGNAL PATH
SG182205A1 (en) * 2007-03-15 2012-07-30 Novartis Ag Organic compounds and their uses
US8399449B2 (en) * 2008-02-26 2013-03-19 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934309B2 (en) 2014-03-31 2021-03-02 Sumitomo Dainippon Pharma Oncology, Inc. Tricyclic quinone derivative

Also Published As

Publication number Publication date
HK1150274A1 (zh) 2011-11-18
MY150379A (en) 2013-12-31
MX2010009372A (es) 2010-09-22
JP2011513199A (ja) 2011-04-28
US8399449B2 (en) 2013-03-19
AU2009217982A1 (en) 2009-09-03
ZA201006063B (en) 2011-10-26
AU2009217982A2 (en) 2010-10-07
CL2009000429A1 (es) 2009-09-25
BRPI0908417B1 (pt) 2022-01-11
IL207735A (en) 2014-12-31
CN102015705A (zh) 2011-04-13
DOP2010000260A (es) 2010-10-15
US20090227561A1 (en) 2009-09-10
BRPI0908417A2 (pt) 2020-08-18
JP5490030B2 (ja) 2014-05-14
US8217176B2 (en) 2012-07-10
AU2009217982B2 (en) 2013-04-11
GEP20125664B (en) 2012-10-10
EA020144B1 (ru) 2014-09-30
ES2586252T3 (es) 2016-10-13
US20110003788A1 (en) 2011-01-06
EP2247588A2 (en) 2010-11-10
CO6321277A2 (es) 2011-09-20
EA201070994A1 (ru) 2011-04-29
JO3259B1 (ar) 2018-09-16
ECSP10010496A (es) 2010-10-30
CN102015705B (zh) 2013-11-13
TW200940548A (en) 2009-10-01
NZ587719A (en) 2012-04-27
CR11661A (es) 2010-10-11
KR101569949B1 (ko) 2015-11-18
CA2716773C (en) 2016-04-26
PE20091556A1 (es) 2009-11-03
KR20100137482A (ko) 2010-12-30
JP4719317B2 (ja) 2011-07-06
JP2011098978A (ja) 2011-05-19
EP2247588B1 (en) 2016-04-13
TWI480282B (zh) 2015-04-11
CA2716773A1 (en) 2009-09-03
WO2009107850A2 (en) 2009-09-03
WO2009107850A3 (en) 2010-01-28
MA32164B1 (fr) 2011-03-01
IL207735A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
AR070479A1 (es) Derivado heterociclico fusionado y su uso
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
DOP2010000183A (es) Derivados de itazol usados como inhibidores de pi 3-cinasa
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
UY31674A1 (es) Derivado heterocíclico fusionado y su uso
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
CO6280399A2 (es) Peptidil nitrilos y uso de los mismos como inhibidores de peptidil peptidasa i
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
CL2011002433A1 (es) Compuestos tetraciclicos, inhibidores de alk; composicion farmaceutica que comprende dichos compuestos, utiles en la profilaxis o el tratamiento de cancer, metastasis de cancer, depresion o un trastorno de la funcion cognitiva.
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
AR066962A1 (es) Compuesto heterociclico fusionado
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
AR066268A1 (es) Compuesto de imidazol sustituido y su uso
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos

Legal Events

Date Code Title Description
FG Grant, registration